Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03914599 · ClinicalTrials.gov registry record
Protective Genetic Factors Against Neurological Diseases
A clinical trial, sponsored by Wayne State University.
- Completed
- Registry status
- 124
- Enrollment target
NCT03914599: Completed study, sponsored by Wayne State University.
NCT03914599 is a clinical trial that has completed, run by Wayne State University. The registered enrollment target is 124 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03914599 has completed, sponsored by Wayne State University.
- COMPLETED
- Registry status
- 124 participants
- Enrollment target
Study Summary
NIH Precision Medicine Initiative, started in May 2018, will enroll one million people through an online portal. It hopes to identify genetic variants affecting a variety of human phenotypic outcomes. A giant set of data like this may enable an association of genetic variants with a certain phenotype. However, the association is often compromised due to the collection of phenotypic data that is not well controlled or standardized creating "noisy" data. These phenotypic "noises" can be largely eliminated in clinical studies with stringent criteria and standardization of outcome measurements. In this study, by looking mainly at genetic information and nerve conduction speed, we hope to eliminate the extra "noises" in the data set. Eliminating the extra "noises" should allow us to be able to determine if there are genetic differences between neurological disorders and healthy controls, and if these genetic differences can be attributed to the speed of the nerve conduction.
Primary Outcome
nerve conduction velocity as measured by electromyogram machine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2019-04-15 |
| Est. Completion | 2022-07-11 |
What the finished NCT03914599 record still lists
NCT03914599 is an observational study that tracks outcomes without assigning an intervention. The registered 124 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT03914599 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03914599 about?
NCT03914599 is a clinical study titled "Protective Genetic Factors Against Neurological Diseases". NIH Precision Medicine Initiative, started in May 2018, will enroll one million people through an online portal. It hopes to identify genetic variants affecting a variety of human phenotypic outcomes. A giant set of data like this may enable an association of genetic variants with a certain phenotyp...
What is the current status of trial NCT03914599?
This trial is currently completed. The enrollment target is 124 participants. The study started on 2019-04-15. Estimated completion is 2022-07-11.
Who is sponsoring clinical trial NCT03914599?
This trial is sponsored by Wayne State University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523014 · 124 participants · Phase 2
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
- NCT02670707 · 124 participants · Phase 3
Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
- NCT02830724 · 124 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
- NCT04748809 · 124 participants · NA
Effect of Anti-inflammatory Diet in Rheumatoid Arthritis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI